GSK gets FDA nod for Blujepa in uncomplicated urogenital gonorrhea

GSK plc GSK announced that the FDA has approved its supplemental new drug application (sNDA) seeking approval for its oral antibiotic Blujepa (gepotidacin) for treating uncomplicated urogenital gonorrhea (uGC) in adult and pediatric patients. The regulatory body has now approved Blujepa as an oral option for adult and pediatric patients aged 12 years and above weighing at least 45 kg who have limited or no alternative options for the treatment...